← Eichor
Study identifier: NCT06059157 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Epileptogenic Network Visualisation With Advanced MRI

Condition: Drug Resistant Epilepsy  ·  Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

PhaseNA
Planned participants80
Who can joinAll sexes, 3 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to improve non-invasive identification of epileptogenic networks in drug-resistant epileptic patient. The investigators aim to compare epileptogenic network identification with stereo-EEG (used as glod standard) with the identification of the same network using advanced MRI (rs-fMRI, microstructural analysis of white matter, ...). The main goals are to: 1. Compare the accuracy of network identification. 2. Analyse the effect of the MRI sequences on candidates selection and target identification. Participants will already have been selected for stereoEEG and will undergo a supplementary MRI (about 1h) with the additional MRI sequences. Follow-up MRI are scheduled for patient undergoing a second, therapeutic epileptic surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Riëm El Tahry, PhD  ·  003227641080  ·  riem.eltahry@saintluc.uclouvain.be

Always discuss trial participation with your own doctor first.

Locations (1)

Cliniques Universitaires St-LucBrussels, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06059157